{"entity":{"id":"andreas-engert","kind":"person","name":"Andreas Engert","aka":[],"tldr":"Led the GHSG for two decades, running the HD10 to HD18 trials that cure over 90% of Hodgkin lymphoma with less treatment.","summary":"Andreas Engert chaired the German Hodgkin Study Group from 2007 to 2020, leading HD10 (two cycles of ABVD plus 20 Gy for early favourable disease), HD15 (six cycles of escalated BEACOPP with PET-guided radiotherapy omission) and HD18, which together defined modern risk- and PET-adapted Hodgkin lymphoma therapy with cure rates above 90%. He was president of the European Hematology Association.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Engert%20A%5BAuthor%5D%20Hodgkin"}],"tags":["hodgkin","ghsg","de-escalation"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":["fdg-pet","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["ghsg"],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine, Hematology and Oncology, University Hospital Cologne; former Chair, German Hodgkin Study Group","institutionId":"uniklinik-koeln","specialisms":["Hodgkin lymphoma","Treatment de-escalation","Cooperative-group trials","Late effects"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Engert%20A%5BAuthor%5D%20Hodgkin"}],"papers":[{"title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma (HD10)","journal":"NEJM","year":2010,"doi":"10.1056/NEJMoa1000067"},{"title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","journal":"Lancet","year":2012,"doi":"10.1016/S0140-6736(11)61940-5"}]},"route":"/people/andreas-engert/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"}],"company":[{"id":"ghsg","kind":"company","name":"German Hodgkin Study Group","route":"/companies/ghsg/"}],"institution":[{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/"}],"trial":[{"id":"hd10","kind":"trial","name":"GHSG HD10","route":"/trials/hd10/"},{"id":"hd16","kind":"trial","name":"GHSG HD16","route":"/trials/hd16/"},{"id":"hd18","kind":"trial","name":"GHSG HD18","route":"/trials/hd18/"}],"paper":[{"id":"paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017","kind":"paper","name":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/"},{"id":"paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019","kind":"paper","name":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}